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toxic regimen might be larger in elderly patients 
with APL, since an older age remains a promi-
nent negative prognostic factor because of the 
high death rate associated with both induction 
therapy and consolidation therapy.2,3 We would 
be grateful if the authors could provide informa-
tion on the efficacy and safety of the regimen of 
ATRA plus arsenic trioxide among elderly pa-
tients in the current trial.
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The authors reply: With respect to elderly pa-
tients, the upper age limit in our study was under 
71 years. Therefore, we can provide data on the 
35 patients between the ages of 60.1 years and 
70.2 years who were included in the trial. A total 
of 16 patients were assigned to receive ATRA plus 
arsenic trioxide, and 19 were assigned to receive 
ATRA plus chemotherapy. There were no signifi-
cant between-group differences in the main pre-
senting features (age, white-cell and platelet 
counts, fibrinogen level, and coagulopathy). The 
24-month event-free survival rates were 100% in 
the group receiving ATRA plus arsenic trioxide 
and 84.2% in the group receiving ATRA plus che-
motherapy (P = 0.40). No patients died and 1 pa-
tient had a relapse at 27 months in the group re-
ceiving ATRA plus arsenic trioxide. In the group 
receiving ATRA plus chemotherapy, 3 patients 
died (1 during induction from the differentiation 
syndrome and 2 during consolidation from pul-
monary embolism and bronchopneumonia). We 
are further investigating the important issue 
raised by Miura et al. by analyzing an extended 
series of elderly patients in our study with pro-
longed follow-up.
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Genomic Landscapes and Clonality of De Novo AML
To the Editor: In reviewing the analysis of the 
genomic and epigenomic landscapes of de novo 
acute myeloid leukemia (AML) by the Cancer Ge-
nome Atlas Research Network (May 30 issue),1 
we were struck by an apparent discrepancy in the 
reported clonal architecture of the AML samples 
as compared with that reported by Ding et al.2 
(an average of one to two distinct clones identi-
fied vs. four or more). This discrepancy may re-
flect the limited depth of the sequencing analysis 
performed in the more recent study.1 More im-
portant, the authors do not reveal which muta-
tions occur in the founding clone, as would be 
expected for an initiator of disease, and which 
occur in minor clones, which subsequently drive 
disease. For instance, FLT3 mutations that are 
present at diagnosis frequently disappear at re-
lapse, which suggests that these mutations are un-
likely to represent initiators of disease in AML.3 
In contrast, DNMT3A mutations present at diag-
nosis appear to occur exclusively in the major 
AML clone, as would be expected in an initiator 
of AML, but are not, it seems, lost (or indeed 
gained) at relapse.4 Such information on these 
and other genes would allow the identification of 
initiating mutations that may serve as therapeu-
tic Achilles’ heels and biomarkers of residual dis-
ease in AML.5
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The Authors Reply: We agree that it is impor-
tant to understand whether mutations are re-
sponsible for the initiation of AML or cooperate 
with initiating mutations to cause disease pro-
gression or relapse.1,2 Whereas initiating muta-
tions may be more likely to appear in founding 
clones, cooperating mutations might appear ei-
ther in founding clones or subclones derived from 
founding clones. In our study, it was not possible 
to define the clonal architecture for all samples, 
both because AML genomes harbor a compara-
tively small number of mutations and because for 
150 of 200 samples, only exome sequencing was 
performed. Nevertheless, we have used the data 
in Table S6 (available with the full text of our 
article at NEJM.org) to identify variants in sig-
nificantly mutated genes that can be assigned 
with high confidence to either a founding clone 
or a subclone. 
Mutations in some genes appear almost ex-
clusively in founding clones, which suggests that 
they are disease initiators. These genes include 
RUNX1 (9 of 9 mutations in founding clones), 
NPM1 (3 of 3), U2AF1 (5 of 5), DNMT3A (38 of 40), 
IDH2 (13 of 14), IDH1 (15 of 17), and KIT (5 of 6). 
In contrast, mutations in NRAS (1 of 12 in found-
ing clones), TET2 (13 of 18), KRAS (4 of 6), CEBPA 
(3 of 5), WT1 (3 of 6), PTPN11 (4 of 8), and FLT3 
(6 of 13), are often found in subclones, suggest-
ing that they are often cooperating mutations. 
Many additional genomes will need to be tested 
to make these tentative assignments more de-
finitive.
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Threshold Insulin-Pump Interruption to Reduce Hypoglycemia
To the Editor: Bergenstal et al. (July 18 issue)1 
report a reduction in nocturnal hypoglycemia 
with the use of the low-glucose (or threshold) 
suspend feature of an insulin pump combined 
with a continuous glucose monitor. Not only was 
the time patients spent in hypoglycemia reduced, 
but also the rate of nocturnal events was 31.8% 
lower in the intervention group. This finding is re-
markable considering that the threshold-suspend 
feature starts to work only when hypoglycemia is 
encountered, not if it is imminent. Could it be 
that suspending insulin administration during a 
hypoglycemic event prevented subsequent events 
during that same night? If that is the case, then 
the number of nights with one or more nocturnal 
hypoglycemic events should be more or less sim-
ilar in the two groups. Could the authors provide 
us with this additional information?
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